Table 2.
The pooled AEs incidence in all-grade or grade ≥3 or individual.
| AEs | Data points | No. | Event rate | 95% CI | Heterogeneity | |
|---|---|---|---|---|---|---|
| I 2 (%) | p for I2 | |||||
| All-grade | 9 | 681 | 0.86 | 0.66–0.98 | 97.0 | <0.01 |
| Grade ≥ 3 | 8 | 471 | 0.21 | 0.17–0.24 | 69.0 | <0.01 |
| Individual AEs | ||||||
| General disorders | ||||||
| Asthenia | 2 | 241 | 0.03 | 0.01–0.06 | 64.0 | 0.09 |
| Back pain | 3 | 470 | 0.07 | 0.02–0.22 | 85.0 | <0.01 |
| Blurred vision | 2 | 27 | 0.15 | 0.06–0.34 | 0.0 | 0.56 |
| Fatigue | 7 | 615 | 0.18 | 0.09–0.31 | 89.0 | <0.01 |
| Infusion-related reactions (IRRs) | 4 | 417 | 0.17 | 0.07–0.36 | 91.0 | <0.01 |
| Nasopharyngitis | 3 | 470 | 0.08 | 0.01–0.34 | 90.0 | <0.01 |
| Oropharyngeal pain | 2 | 453 | 0.10 | 0.08–0.13 | 57.0 | 0.13 |
| Pyrexia | 6 | 650 | 0.28 | 0.22–0.36 | 66.0 | 0.01 |
| Upper respiratory tract infection | 5 | 576 | 0.07 | 0.02–0.22 | 89.0 | <0.01 |
| Gastrointestinal disorders | ||||||
| Abdominal pain | 2 | 304 | 0.14 | 0.11–0.19 | 0.0 | 0.94 |
| Constipation | 5 | 562 | 0.08 | 0.04–0.16 | 74.0 | <0.01 |
| Diarrhea | 8 | 691 | 0.15 | 0.08–0.28 | 88.0 | <0.01 |
| Nausea | 6 | 598 | 0.18 | 0.09–0.33 | 90.0 | <0.01 |
| Vomiting | 4 | 545 | 0.11 | 0.05–0.24 | 88.0 | <0.01 |
| Skin disorders | ||||||
| Myalgia | 5 | 541 | 0.10 | 0.05–0.18 | 74.0 | <0.01 |
| Nasal congestion | 3 | 514 | 0.08 | 0.03–0.21 | 89.0 | <0.01 |
| Rash | 8 | 690 | 0.18 | 0.13–0.25 | 69.0 | <0.01 |
| Pruritus | 6 | 564 | 0.17 | 0.09–0.31 | 85.0 | <0.01 |
| Hepatic disorders | ||||||
| ALT level increased | 2 | 274 | 0.08 | 0.05–0.11 | 0.0 | 0.79 |
| AST level increased | 2 | 274 | 0.07 | 0.05–0.11 | 0.0 | 0.85 |
| Hepatic function abnormal | 2 | 113 | 0.05 | 0.02–0.12 | 55.0 | 0.14 |
| Lipase level increased | 2 | 119 | 0.07 | 0.03–0.13 | 0.0 | 0.68 |
| Thyroid disorders | ||||||
| Hypothyroidism | 5 | 410 | 0.16 | 0.09–0.26 | 72.0 | <0.01 |
| Thyroiditis | 2 | 274 | 0.02 | 0.00–0.16 | 77.0 | 0.04 |
| Musculoskeletal disorders | ||||||
| Arthralgia | 3 | 514 | 0.10 | 0.04–0.24 | 89.0 | <0.01 |
| Respiratory disorders | ||||||
| Chills | 3 | 302 | 0.07 | 0.02–0.23 | 85.0 | <0.01 |
| Cough | 4 | 537 | 0.15 | 0.05–0.36 | 94.0 | <0.01 |
| Dyspnea | 5 | 555 | 0.09 | 0.04–0.19 | 80.0 | <0.01 |
| Pneumonia | 4 | 380 | 0.11 | 0.08–0.15 | 0.0 | 0.99 |
| Nervous system disorders | ||||||
| Dizziness | 2 | 78 | 0.13 | 0.07–0.22 | 0.0 | 0.88 |
| Headache | 3 | 321 | 0.20 | 0.16–0.25 | 0.0 | 0.58 |
| Peripheral sensory neuropathy | 2 | 71 | 0.32 | 0.05–0.80 | 88.0 | <0.01 |
| Blood and lymphatic system disorders | ||||||
| Alanine aminotransferase increased | 3 | 349 | 0.14 | 0.03–0.45 | 92.0 | <0.01 |
| Alkaline phosphatase increased | 4 | 380 | 0.06 | 0.04–0.09 | 31.0 | 0.22 |
| Anemia | 2 | 306 | 0.09 | 0.06–0.12 | 0.0 | 0.61 |
| Aspartate aminotransferase increased | 3 | 349 | 0.09 | 0.02–0.37 | 90.0 | <0.01 |
| Decreased lymphocyte count | 5 | 701 | 0.05 | 0.04–0.07 | 0.0 | 0.72 |
| Decreased platelet count | 2 | 119 | 0.13 | 0.08–0.20 | 0.0 | 0.44 |